ClinicalTrials.gg
CompletedNCT03715829Updated Mar 25, 2022Results posted

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

A Phase 2 interventional study of PF-06651600 and PF-06651600 in Active Non-segmental Vitiligo, sponsored by Pfizer. Completed at 92 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Enrollment
8th of 68
366 · median 37
Started
2018
with 3 others
Phase 2
31 of 80
6 open now
Registered
30th of 80
by date
Lead sponsor
4 of 80
Pfizer

Among the 80 studies in Vitiligo with a site in United States, this one is the 8th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2018, is one of 31 in phase 2, and was the 30th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week Follow up Period.

03

Conditions studied

  • Active Non-segmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18-65 years of age, inclusive, at time of .
  • Must have moderate to severe active non-segmental vitiligo.

Exclusion criteria

Exclusion Criteria:

  • History of (HIV) or positive HIV serology at screening,
  • Infected with or viruses.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks

    Drug: PF-06651600

  • Experimental
    Cohort 2

    Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks

    Drug: PF-06651600

  • Experimental
    Cohort 3

    Maintenance dose A given QD for 24 weeks

    Drug: PF-06651600

  • Experimental
    Cohort 4

    Maintenance dose B given QD for 24 weeks

    Drug: PF-06651600

  • Experimental
    Cohort 5

    Maintenance dose C given QD for 24 weeks

    Drug: PF-06651600

  • Placebo comparator
    Cohort 6

    Placebo given QD for 24 weeks

    Drug: placebo

  • Experimental
    Extension Cohort 1

    4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks

    Drug: PF06700841

  • Experimental
    Extension Cohort 2

    Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy

    Drug: PF-06651600 · Device: narrow-band UVB phototherapy

  • Experimental
    Extension Cohort 3

    Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks

    Drug: PF-06651600

  • Experimental
    Extension Cohort 4

    Maintenance dose A given QD for 24 weeks

    Drug: PF-06651600

  • Experimental
    Extension Cohort 5

    Maintenance dose B given QD for 24 weeks

    Drug: PF-06651600

  • No intervention
    Extension Cohort 6

    Observation period for 24 weeks

Interventions

  • Induction dose 1. Oral tablet taken QD

  • Induction dose 2. Oral tablet taken QD

  • Maintenance dose A. Oral tablet taken QD

  • Maintenance Dose B. Oral tablet taken QD

  • Maintenance Dose C. Oral tablet taken QD

  • Drugplacebo

    placebo

  • Oral tablet taken QD

  • Devicenarrow-band UVB phototherapy

    Phototherapy will be combined with PF-06651600

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period

    Central read F-VASI was assessed based on the facial photographs taken at the site. Central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. The higher score of F-VASI signified severer symptoms of non-segmental vitiligo. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)×100. A negative percent change from baseline in central read F-VASI signified an improvement.

    Time frame: Baseline, Week 24 (Baseline was defined as the last measurement prior to Study Day 18)

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to Week 24 - DR Period

    Adverse Event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator.

    Time frame: 24 weeks

  3. Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - DR Period

    An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline up to Week 24

  4. Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile up to Week 24 - DR Period

    Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline up to Week 24

  5. Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - DR Period

    Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin.

    Time frame: 24 weeks

  6. Number of Participants With TEAEs and SAEs - Extension (Ext) Period

    AE was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator.

    Time frame: 24 weeks

  7. Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - Ext Period

    An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.

    Time frame: 24 weeks

  8. Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile - Ext Period

    Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator.

    Time frame: 24 Weeks

  9. Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - Ext Period

    Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin.

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of Participants Achieving Central F-VASI75 at Week 24 - DR Period

    This outcome measure was the percentage of participants achieving at least 75% improvement from baseline in central read F-VASI (F-VASI75) at Week 24. A negative percent change from baseline in central read F-VASI signified an improvement. The central read F-VASI75 response rate was analyzed by first treating the missing data (non-COVID-19 related) as non responders and then applying Chan and Zhang exact confidence interval (CI) method at Week 24. Central read F-VASI75=1 if percent change from baseline ≥75; central read F-VASI75=0 if percent change from baseline \<75. Percent change from baseline in F-VASI=((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. Baseline was defined as the last measurement prior to study Day 18.

    Time frame: Week 24

  2. Percentage of Participants Achieving T-VASI50 at Week 24 - DR Period

    Total body VASI (T-VASI) was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: T-VASI= Ʃ\[Hand Units\]×\[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding feet), and feet. The extent of depigmentation was expressed by percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The data below was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50) at Week 24. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Week 24

  3. Percent Change From Baseline in T-VASI at Designated Time Points - DR Period

    The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  4. Percent Change From Baseline in Central Read F-VASI at Designated Time Points - DR Period

    The central read F-VASI was assessed based on the facial photographs taken at the site. The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)×100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

    Time frame: Baseline, Weeks 4, 8, 16 and 24

  5. Percent Change From Baseline in Local F-VASI at Designated Time Points - DR Period

    The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0.00 4.00): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  6. Percent Change From Baseline in SA-VES at Designated Time Points - DR Period

    The Self-Assessment Vitiligo Extent Score (SA-VES) was a validated patient report outcome measurement instrument to provide information about disease extent. Vitiligo Extent Score (VES) was a measure to express the overall vitiligo involvement of the body (extent). Clinical illustrations for 19 separate body areas that reflected different degrees of involvement (1%, 5%, 10%, 25%, 50% and 75% depigmentation) were chosen to represent the participant's skin lesions to get the total extent of the disease. VES was a sum of all surface measurement that was similar to VASI. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 16 and 24

  7. Absolute Change From Baseline in T-VASI at Designated Time Points - DR Period

    The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. The absolute change from baseline in T-VASI was analyzed using the ANCOVA analysis. Negative change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  8. Percentage of Participants Achieving T-VASI50 at Designated Time Points - DR Period

    T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  9. Percentage of Participants Achieving T-VASI75 at Designated Time Points - DR Period

    T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 75% improvement from baseline in T-VASI (T-VASI75). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  10. Percentage of Participants Achieving T-VASI90 at Designated Time Points - DR Period

    T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 90% improvement from baseline in T-VASI (T-VASI90). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  11. Percentage of Participants Achieving T-VASI100 at Designated Time Points - DR Period

    T-VASI was calculated using a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. This outcome measure was the percentage of participants achieving 100% improvement from baseline in T-VASI (T-VASI100). Percent change from baseline in T-VASI = ((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  12. Percentage of Participants Achieving Central Read F-VASI50 at Designated Time Points - DR Period

    The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 50% improvement in central read F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

    Time frame: Baseline, Weeks 4, 8, 16 and 24

  13. Percentage of Participants Achieving Central Read F-VASI75 at Designated Time Points - DR Period

    The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 75% improvement in central read F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

    Time frame: Baseline, Weeks 4, 8, 16 and 24

  14. Percentage of Participants Achieving Central Read F-VASI90 at Designated Time Points - DR Period

    The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 90% improvement in central read F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

    Time frame: Baseline, Weeks 4, 8, 16 and 24

  15. Percentage of Participants Achieving Central Read F-VASI100 at Designated Time Points - DR Period

    The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 100% improvement in central read F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

    Time frame: Baseline, Weeks 4, 8, 16 and 24

  16. Percentage of Participants Achieving Local F-VASI50 at Designated Time Points - DR Period

    The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 50% improvement in site assessment F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  17. Percentage of Participants Achieving Local F-VASI75 at Designated Time Points - DR Period

    The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 75% improvement in site assessment F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  18. Percentage of Participants Achieving Local F-VASI90 at Designated Time Points - DR Period

    The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 90% improvement in site assessment F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  19. Percentage of Participants Achieving Local F-VASI100 at Designated Time Points - DR Period

    The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving 100% improvement in site assessment F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  20. Change From Baseline in Total VitiQoL Score at Designated Time Points - DR Period

    The Vitiligo-Specific Quality of Life (VitiQoL) instrument was a reliable and validated vitiligo disease-specific health-related quality of life (HRQoL) instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL total score was calculated as sum of items 1-15. The change from baseline in total VitiQoL score was analyzed using the mixed-effect models repeated measures (MMRM) analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 16 and 24

  21. Change From Baseline in VitiQoL Participation Limitation Domain Score at Designated Time Points - DR Period

    The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Participation Limitation domain score was the sum of items 3, 4, 6, 9, 10, 11, 14 and ranged from 0 to 42. The change from baseline in VitiQoL Participation Limitation Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 16 and 24

  22. Change From Baseline in VitiQoL Stigma Domain Score at Designated Time Points - DR Period

    The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Stigma domain score was the sum of items 1, 2, 5, 7 and 15, and ranged from 0 to 30. The change from baseline in VitiQoL Stigma Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 16 and 24

  23. Change From Baseline in VitiQoL Behaviors Domain Score at Designated Time Points - DR Period

    The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Behaviors domain score was the sum of items 8, 12 and 13, and ranged from 0 to 18. The change from baseline in VitiQoL Behaviors Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Weeks 4, 16 and 24

  24. Percentage of Participants Achieving sIGA 0 or 1 and at Least a 2-Point Improvement at Week 24 - DR Period

    The percentage of participants achieving a static Investigator Global Assessment (sIGA) Score 0/1 and sIGA ≥2-point improvement at Week 24 was presented in this outcome measure. The sIGA score ranged from 0 to 4. The sIGA Score 0 represented "Clear" with no signs of loss of pigmentation with natural light or with Woods lamp examination. The sIGA Score 1 represented "Almost Clear" with the following descriptors: * Faint, barely detectable loss of pigmentation mainly located on dorsal hands, feet, bony prominences, and/or limited areas. * Approximately 90% pigmentation within lesions. * No or rare signs of Koebner phenomenon, confetti like or trichrome lesions could be present. The sIGA Scores 2, 3 and 4 represented "Mild Vitiligo", "Moderate Vitiligo" and "Severe Vitiligo", respectively.

    Time frame: Week 24

07

Results

Posted Mar 25, 2022

Participant flow

Dose Ranging Period
Participant flow — Dose Ranging Period
MilestonePF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlaceboExtension (EXT) PF-06700841 60 mg - 30 mg QDEXT PF-06651600 200 Mg-50 mg QD + nbUVBEXT PF-06651600 200 mg - 50 mg QDEXT PF-06651600 50 mg QDEXT PF-06651600 30 mg QD
Started65676750496600000
Completed53585436425500000
Not completed129131471100000
Withdrew: Adverse event24523300000
Withdrew: Lack of efficacy01010000000
Withdrew: Lost to follow-up20111200000
Withdrew: Protocol violation00010000000
Withdrew: Withdrawal by subject84392300000
Withdrew: Medication error without associated adverse event00100000000
Withdrew: No longer meets eligibility criteria00101000000
Withdrew: Other00200300000
Extension Period
Participant flow — Extension Period
MilestonePF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlaceboExtension (EXT) PF-06700841 60 mg - 30 mg QDEXT PF-06651600 200 Mg-50 mg QD + nbUVBEXT PF-06651600 200 mg - 50 mg QDEXT PF-06651600 50 mg QDEXT PF-06651600 30 mg QD
Started000000554318762
Completed000000472715832
Not completed0000008162930
Withdrew: Adverse event00000031600
Withdrew: Lack of efficacy00000019200
Withdrew: Lost to follow-up00000000200
Withdrew: Protocol violation00000000100
Withdrew: Withdrawal by subject000000331230
Withdrew: Medication error without associated adverse event00000001100
Withdrew: No longer meets eligibility criteria00000000100
Withdrew: Other00000012400

Outcome measures

PrimaryPercent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period

Central read F-VASI was assessed based on the facial photographs taken at the site. Central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. The higher score of F-VASI signified severer symptoms of non-segmental vitiligo. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)×100. A negative percent change from baseline in central read F-VASI signified an improvement.

Time frame:
Baseline, Week 24 (Baseline was defined as the last measurement prior to Study Day 18)
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period
Percent ChangePF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period-21.2 ± 4.13-21.2 ± 4.16-18.5 ± 4.44-14.6 ± 5.47-3.0 ± 4.652.1 ± 4.06
Statistical analysis
  • PF-06651600 200 mg - 50 mg QD vs Placebo · ANCOVA · p = <0.0001 (Hochberg's step-up procedure was conducted to compare ritlecitinib 200mg - 50mg QD dose group vs placebo using observed p-values. The familywise Type 1 error rate was controlled at one-sided 0.05. Hochberg adjusted p-value is presented here.) · Least squares mean difference (net): -23.2 · 90% CI -32.53 to -13.96
  • PF-06651600 100 mg - 50 mg QD vs Placebo · ANCOVA · p = <0.0001 (Hochberg's step-up procedure was conducted to compare ritlecitinib 100mg - 50mg QD dose group vs placebo using observed p-values. The familywise Type 1 error rate was controlled at one-sided 0.05. Hochberg adjusted p-value is presented here.) · Least squares mean difference (net): -23.2 · 90% CI -32.53 to -13.93
  • PF-06651600 50 mg QD vs Placebo · ANCOVA · p = 0.0003 (Hochberg's step-up procedure was conducted to compare the ritlecitinib 50 mg QD dose group vs placebo using observed p-values. The familywise Type 1 error rate was controlled at one-sided 0.05. Hochberg adjusted p-value is presented here.) · Least squares mean difference (net): -20.6 · 90% CI -30.23 to -10.93
  • PF-06651600 30 mg QD vs Placebo · ANCOVA · p = 0.0068 (Hochberg's step-up procedure was conducted to compare the ritlecitinib 30 mg QD dose group vs placebo using observed p-values. The familywise Type 1 error rate was controlled at one-sided 0.05. One-sided unadjusted p-value is presented here.) · Least squares mean difference (net): -16.7 · 90% CI -27.77 to -5.61
  • PF-06651600 10 mg QD · ANCOVA · p = 0.2015 (Hochberg's step-up procedure was conducted to compare the ritlecitinib 10 mg QD dose group vs placebo using observed p-values. The familywise Type 1 error rate was controlled at one-sided 0.05. One-sided unadjusted p-value is presented here.) · Least squares mean difference (net): -5.1 · 90% CI -15.02 to 4.91
SecondaryPercentage of Participants Achieving Central F-VASI75 at Week 24 - DR Period

This outcome measure was the percentage of participants achieving at least 75% improvement from baseline in central read F-VASI (F-VASI75) at Week 24. A negative percent change from baseline in central read F-VASI signified an improvement. The central read F-VASI75 response rate was analyzed by first treating the missing data (non-COVID-19 related) as non responders and then applying Chan and Zhang exact confidence interval (CI) method at Week 24. Central read F-VASI75=1 if percent change from baseline ≥75; central read F-VASI75=0 if percent change from baseline \<75. Percent change from baseline in F-VASI=((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. Baseline was defined as the last measurement prior to study Day 18.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Central F-VASI75 at Week 24 - DR Period
Percentage of ParticipantsPF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Percentage of Participants Achieving Central F-VASI75 at Week 24 - DR Period12.18.57.72.72.30
SecondaryPercentage of Participants Achieving T-VASI50 at Week 24 - DR Period

Total body VASI (T-VASI) was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: T-VASI= Ʃ\[Hand Units\]×\[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding feet), and feet. The extent of depigmentation was expressed by percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The data below was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50) at Week 24. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving T-VASI50 at Week 24 - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Percentage of Participants Achieving T-VASI50 at Week 24 - DR Period7.94.64.610.64.19.1
SecondaryPercent Change From Baseline in T-VASI at Designated Time Points - DR Period

The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in T-VASI at Designated Time Points - DR Period
Percent ChangePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4-2.4 ± 1.51-3.0 ± 1.50-2.6 ± 1.50-5.1 ± 1.72-2.9 ± 1.76-1.4 ± 1.52
Week 8-6.2 ± 2.03-5.4 ± 2.01-5.1 ± 2.01-6.6 ± 2.33-3.0 ± 2.32-5.8 ± 2.02
Week 12-7.2 ± 2.44-11.9 ± 2.40-9.1 ± 2.40-11.4 ± 2.82-4.9 ± 2.76-8.0 ± 2.40
Week 16-10.0 ± 2.66-13.1 ± 2.67-12.6 ± 2.66-11.9 ± 3.03-5.7 ± 3.03-12.0 ± 2.62
Week 20-13.8 ± 3.13-16.0 ± 2.98-14.2 ± 3.07-12.0 ± 3.43-9.2 ± 3.51-13.3 ± 3.04
Week 24-14.7 ± 3.49-19.2 ± 3.29-14.7 ± 3.44-14.0 ± 4.15-12.1 ± 3.88-11.0 ± 3.34
SecondaryPercent Change From Baseline in Central Read F-VASI at Designated Time Points - DR Period

The central read F-VASI was assessed based on the facial photographs taken at the site. The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)×100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

Time frame:
Baseline, Weeks 4, 8, 16 and 24
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Central Read F-VASI at Designated Time Points - DR Period
Percent ChangePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 40.1 ± 0.800.4 ± 0.82-0.2 ± 0.84-1.2 ± 0.940.0 ± 0.910.6 ± 0.83
Week 8-7.0 ± 1.42-5.3 ± 1.44-1.8 ± 1.46-1.4 ± 1.62-0.1 ± 1.55-0.2 ± 1.44
Week 16-17.0 ± 3.16-16.4 ± 3.25-10.7 ± 3.19-13.3 ± 3.87-5.6 ± 3.67-0.2 ± 3.27
Week 24-21.2 ± 4.13-21.2 ± 4.16-18.5 ± 4.44-14.6 ± 5.47-3.0 ± 4.652.1 ± 4.06
SecondaryPercent Change From Baseline in Local F-VASI at Designated Time Points - DR Period

The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0.00 4.00): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Local F-VASI at Designated Time Points - DR Period
Percent ChangePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4-4.9 ± 2.633.1 ± 2.61-5.0 ± 2.600.4 ± 2.96-5.3 ± 3.05-6.3 ± 2.63
Week 8-11.3 ± 5.350.4 ± 5.32-8.8 ± 5.3010.1 ± 6.09-7.3 ± 6.12-7.5 ± 5.31
Week 12-15.9 ± 4.16-6.5 ± 4.11-12.2 ± 4.10-7.1 ± 4.77-9.8 ± 4.72-11.4 ± 4.08
Week 16-19.4 ± 4.85-6.2 ± 4.88-19.7 ± 4.82-6.4 ± 5.48-10.3 ± 5.46-13.3 ± 4.75
Week 20-21.9 ± 5.59-12.9 ± 5.35-23.2 ± 5.520.0 ± 6.11-14.4 ± 6.30-15.3 ± 5.44
Week 24-28.3 ± 5.70-20.6 ± 5.38-26.2 ± 5.61-4.3 ± 6.70-13.9 ± 6.32-18.1 ± 5.43
SecondaryPercent Change From Baseline in SA-VES at Designated Time Points - DR Period

The Self-Assessment Vitiligo Extent Score (SA-VES) was a validated patient report outcome measurement instrument to provide information about disease extent. Vitiligo Extent Score (VES) was a measure to express the overall vitiligo involvement of the body (extent). Clinical illustrations for 19 separate body areas that reflected different degrees of involvement (1%, 5%, 10%, 25%, 50% and 75% depigmentation) were chosen to represent the participant's skin lesions to get the total extent of the disease. VES was a sum of all surface measurement that was similar to VASI. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 16 and 24
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in SA-VES at Designated Time Points - DR Period
Percent ChangePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 42.7 ± 17.191.1 ± 16.71-1.1 ± 16.744.9 ± 19.254.9 ± 19.8450.4 ± 17.13
Week 164.7 ± 13.82-0.5 ± 13.48-3.7 ± 13.456.9 ± 15.53-0.5 ± 15.8752.5 ± 13.72
Week 240.0 ± 10.35-3.5 ± 10.02-4.3 ± 10.11-4.4 ± 11.89-1.6 ± 11.7744.0 ± 10.16
SecondaryAbsolute Change From Baseline in T-VASI at Designated Time Points - DR Period

The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. The absolute change from baseline in T-VASI was analyzed using the ANCOVA analysis. Negative change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Least squares mean · Units on a Scale
Absolute Change From Baseline in T-VASI at Designated Time Points - DR Period
Units on a ScalePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4-0.3 ± 0.25-0.5 ± 0.25-0.6 ± 0.25-1.0 ± 0.28-0.4 ± 0.29-0.2 ± 0.25
Week 8-0.9 ± 0.32-0.9 ± 0.32-0.9 ± 0.32-1.2 ± 0.37-0.5 ± 0.36-0.9 ± 0.32
Week 12-1.1 ± 0.41-2.0 ± 0.40-1.6 ± 0.40-1.8 ± 0.47-0.9 ± 0.46-1.6 ± 0.40
Week 16-1.5 ± 0.46-2.1 ± 0.46-1.9 ± 0.46-1.9 ± 0.53-0.9 ± 0.53-2.2 ± 0.46
Week 20-2.0 ± 0.55-2.8 ± 0.53-2.3 ± 0.54-2.0 ± 0.61-1.7 ± 0.62-2.2 ± 0.54
Week 24-2.3 ± 0.62-3.4 ± 0.59-2.4 ± 0.61-2.7 ± 0.74-2.0 ± 0.69-1.8 ± 0.60
SecondaryPercentage of Participants Achieving T-VASI50 at Designated Time Points - DR Period

T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving T-VASI50 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 41.61.502.000
Week 81.61.51.54.001.5
Week 121.61.51.54.104.5
Week 1603.202.106.3
Week 204.91.51.66.12.19.5
Week 247.94.64.610.64.19.1
SecondaryPercentage of Participants Achieving T-VASI75 at Designated Time Points - DR Period

T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 75% improvement from baseline in T-VASI (T-VASI75). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving T-VASI75 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000000
Week 8000000
Week 12000000
Week 16000000
Week 20000000
Week 24000000
SecondaryPercentage of Participants Achieving T-VASI90 at Designated Time Points - DR Period

T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 90% improvement from baseline in T-VASI (T-VASI90). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving T-VASI90 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000000
Week 8000000
Week 12000000
Week 16000000
Week 20000000
Week 24000000
SecondaryPercentage of Participants Achieving T-VASI100 at Designated Time Points - DR Period

T-VASI was calculated using a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. This outcome measure was the percentage of participants achieving 100% improvement from baseline in T-VASI (T-VASI100). Percent change from baseline in T-VASI = ((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving T-VASI100 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000000
Week 8000000
Week 12000000
Week 16000000
Week 20000000
Week 24000000
SecondaryPercentage of Participants Achieving Central Read F-VASI50 at Designated Time Points - DR Period

The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 50% improvement in central read F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

Time frame:
Baseline, Weeks 4, 8, 16 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Central Read F-VASI50 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 40002.200
Week 83.2002.200
Week 1614.813.86.910.32.41.9
Week 2422.425.415.418.97.01.8
SecondaryPercentage of Participants Achieving Central Read F-VASI75 at Designated Time Points - DR Period

The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 75% improvement in central read F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

Time frame:
Baseline, Weeks 4, 8, 16 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Central Read F-VASI75 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000000
Week 8000000
Week 161.61.75.22.62.40
Week 2412.18.57.72.72.30
SecondaryPercentage of Participants Achieving Central Read F-VASI90 at Designated Time Points - DR Period

The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 90% improvement in central read F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

Time frame:
Baseline, Weeks 4, 8, 16 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Central Read F-VASI90 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000000
Week 8000000
Week 16001.7000
Week 241.703.8000
SecondaryPercentage of Participants Achieving Central Read F-VASI100 at Designated Time Points - DR Period

The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 100% improvement in central read F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.

Time frame:
Baseline, Weeks 4, 8, 16 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Central Read F-VASI100 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000000
Week 8000000
Week 16000000
Week 24000000
SecondaryPercentage of Participants Achieving Local F-VASI50 at Designated Time Points - DR Period

The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 50% improvement in site assessment F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Local F-VASI50 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 43.13.01.52.003.0
Week 89.43.04.52.04.14.5
Week 1216.19.19.18.28.39.1
Week 1614.39.713.68.510.614.3
Week 2018.014.917.212.216.717.5
Week 2420.621.515.410.618.416.7
SecondaryPercentage of Participants Achieving Local F-VASI75 at Designated Time Points - DR Period

The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 75% improvement in site assessment F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Local F-VASI75 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000001.5
Week 8003.02.000
Week 121.63.04.56.12.11.5
Week 163.204.54.34.37.9
Week 206.61.59.46.16.311.1
Week 2411.14.66.24.34.113.6
SecondaryPercentage of Participants Achieving Local F-VASI90 at Designated Time Points - DR Period

The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 90% improvement in site assessment F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Local F-VASI90 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000000
Week 8001.52.000
Week 12001.52.000
Week 161.603.02.12.10
Week 201.61.54.72.02.11.6
Week 241.61.53.104.11.5
SecondaryPercentage of Participants Achieving Local F-VASI100 at Designated Time Points - DR Period

The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving 100% improvement in site assessment F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Local F-VASI100 at Designated Time Points - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4000000
Week 80002.000
Week 12000000
Week 16000000
Week 20001.6000
Week 24001.5000
SecondaryChange From Baseline in Total VitiQoL Score at Designated Time Points - DR Period

The Vitiligo-Specific Quality of Life (VitiQoL) instrument was a reliable and validated vitiligo disease-specific health-related quality of life (HRQoL) instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL total score was calculated as sum of items 1-15. The change from baseline in total VitiQoL score was analyzed using the mixed-effect models repeated measures (MMRM) analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 16 and 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Total VitiQoL Score at Designated Time Points - DR Period
Units on a ScalePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4-3.9 ± 1.34-2.9 ± 1.31-4.4 ± 1.31-4.4 ± 1.50-3.5 ± 1.54-5.1 ± 1.33
Week 16-6.5 ± 1.83-4.9 ± 1.79-6.3 ± 1.82-4.8 ± 2.07-10.5 ± 2.06-7.1 ± 1.78
Week 24-6.5 ± 1.99-3.6 ± 1.92-7.7 ± 1.99-7.0 ± 2.30-9.7 ± 2.22-6.4 ± 1.92
SecondaryChange From Baseline in VitiQoL Participation Limitation Domain Score at Designated Time Points - DR Period

The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Participation Limitation domain score was the sum of items 3, 4, 6, 9, 10, 11, 14 and ranged from 0 to 42. The change from baseline in VitiQoL Participation Limitation Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 16 and 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in VitiQoL Participation Limitation Domain Score at Designated Time Points - DR Period
Units on a ScalePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4-1.2 ± 0.71-1.1 ± 0.69-1.7 ± 0.69-1.8 ± 0.79-1.0 ± 0.81-2.5 ± 0.70
Week 16-2.1 ± 0.88-1.9 ± 0.86-2.6 ± 0.87-2.3 ± 1.00-4.1 ± 0.99-3.1 ± 0.85
Week 24-1.4 ± 0.98-1.7 ± 0.94-3.2 ± 0.97-2.8 ± 1.14-3.9 ± 1.09-2.2 ± 0.94
SecondaryChange From Baseline in VitiQoL Stigma Domain Score at Designated Time Points - DR Period

The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Stigma domain score was the sum of items 1, 2, 5, 7 and 15, and ranged from 0 to 30. The change from baseline in VitiQoL Stigma Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 16 and 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in VitiQoL Stigma Domain Score at Designated Time Points - DR Period
Units on a ScalePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4-1.9 ± 0.56-1.6 ± 0.55-2.4 ± 0.55-1.7 ± 0.62-1.7 ± 0.64-1.8 ± 0.56
Week 16-3.4 ± 0.71-2.3 ± 0.70-3.2 ± 0.71-1.7 ± 0.80-4.3 ± 0.80-2.9 ± 0.69
Week 24-3.8 ± 0.76-2.1 ± 0.73-3.7 ± 0.76-3.1 ± 0.88-4.5 ± 0.84-3.2 ± 0.73
SecondaryChange From Baseline in VitiQoL Behaviors Domain Score at Designated Time Points - DR Period

The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Behaviors domain score was the sum of items 8, 12 and 13, and ranged from 0 to 18. The change from baseline in VitiQoL Behaviors Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Weeks 4, 16 and 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in VitiQoL Behaviors Domain Score at Designated Time Points - DR Period
Units on a ScalePF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Week 4-0.8 ± 0.37-0.3 ± 0.36-0.2 ± 0.36-0.9 ± 0.41-0.7 ± 0.42-0.7 ± 0.37
Week 16-1.1 ± 0.50-0.8 ± 0.49-0.5 ± 0.50-0.9 ± 0.57-2.1 ± 0.56-1.0 ± 0.49
Week 24-1.4 ± 0.530 ± 0.52-0.7 ± 0.53-1.3 ± 0.62-1.3 ± 0.60-0.9 ± 0.51
SecondaryPercentage of Participants Achieving sIGA 0 or 1 and at Least a 2-Point Improvement at Week 24 - DR Period

The percentage of participants achieving a static Investigator Global Assessment (sIGA) Score 0/1 and sIGA ≥2-point improvement at Week 24 was presented in this outcome measure. The sIGA score ranged from 0 to 4. The sIGA Score 0 represented "Clear" with no signs of loss of pigmentation with natural light or with Woods lamp examination. The sIGA Score 1 represented "Almost Clear" with the following descriptors: * Faint, barely detectable loss of pigmentation mainly located on dorsal hands, feet, bony prominences, and/or limited areas. * Approximately 90% pigmentation within lesions. * No or rare signs of Koebner phenomenon, confetti like or trichrome lesions could be present. The sIGA Scores 2, 3 and 4 represented "Mild Vitiligo", "Moderate Vitiligo" and "Severe Vitiligo", respectively.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving sIGA 0 or 1 and at Least a 2-Point Improvement at Week 24 - DR Period
Percentage of ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Percentage of Participants Achieving sIGA 0 or 1 and at Least a 2-Point Improvement at Week 24 - DR Period000000
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to Week 24 - DR Period

Adverse Event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to Week 24 - DR Period
ParticipantsPF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Participants With All-Causality TEAEs564554304052
Participants With Treatment-Related TEAEs321920171820
Participants With All-Causality SAEs001111
Participants With Treatment-Related SAEs000000
PrimaryNumber of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - DR Period

An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - DR Period
ParticipantsPF-06651600 200mg - 50mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Participants With Anaemia000000
Participants With Neutropenia010011
Participants With Thrombocytopenia100000
Participants With Lymphopenia100000
PrimaryNumber of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile up to Week 24 - DR Period

Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator. Baseline was defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile up to Week 24 - DR Period
ParticipantsPF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile up to Week 24 - DR Period000000
PrimaryNumber of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - DR Period

Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - DR Period
ParticipantsPF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlacebo
Bilirubin > 1.5 x upper limit of normal (ULN)000000
AST > 2.5 x ULN101010
ALT > 2.5 x ULN001111
PrimaryNumber of Participants With TEAEs and SAEs - Extension (Ext) Period

AE was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and SAEs - Extension (Ext) Period
ParticipantsExtension (EXT) PF-06700841 60 mg - 30 mg QDEXT PF-06651600 200 Mg-50 mg QD + nbUVBEXT PF-06651600 200 mg - 50 mg QDEXT PF-06651600 50 mg QDEXT PF-06651600 30 mg QD
Participants With All-Causality TEAEs383211932
Participants With Treatment-Related TEAEs20123600
Participants With All-Causality SAEs10100
Participants With Treatment-Related SAEs10000
PrimaryNumber of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - Ext Period

An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - Ext Period
ParticipantsExtension (EXT) PF-06700841 60 mg - 30 mg QDEXT PF-06651600 200 Mg-50 mg QD + nbUVBEXT PF-06651600 200 mg - 50 mg QDEX PF-06651600 50mg QDEXT PF-06651600 30 mg QD
Participants With Anemia00010
Participants With Neutropenia10100
Participants With Thrombocytopenia00000
Participants With Lymphopenia00000
PrimaryNumber of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile - Ext Period

Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator.

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile - Ext Period
ParticipantsExtension (EXT) PF-06700841 60 mg - 30 mg QDEXT PF-06651600 200 Mg-50 mg QD + nbUVBEXT PF-06651600 200 mg - 50 mg QDEXT PF-06651600 50 mg QDEXT PF-06651600 30 mg QD
Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile - Ext Period00000
PrimaryNumber of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - Ext Period

Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - Ext Period
ParticipantsExtension (EXT) PF-06700841 60 mg - 30 mg QDEXT PF-06651600 200 Mg-50 mg QD + nbUVBEXT PF-06651600 200 mg - 50 mg QDEXT PF-06651600 50 mg QDEXT PF-06651600 30 mg QD
Bilirubin > 1.5 x ULN00000
AST > 2.5 x ULN00000
ALT > 2.5 x ULN00100

Adverse events

Collected over 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06651600 200 mg - 50 mg QD0/65 (0%)0/65 (0%)31/65 (47.7%)
PF-06651600 100 mg - 50 mg QD0/67 (0%)0/67 (0%)35/67 (52.2%)
PF-06651600 50 mg QD0/67 (0%)1/67 (1.5%)32/67 (47.8%)
PF-06651600 30 mg QD0/50 (0%)1/50 (2%)23/50 (46%)
PF-06651600 10 mg QD0/49 (0%)1/49 (2%)22/49 (44.9%)
Placebo0/66 (0%)1/66 (1.5%)37/66 (56.1%)
Extension (EXT) PF-06700841 60 mg - 30 mg QD0/55 (0%)1/55 (1.8%)17/55 (30.9%)
EX PF-06651600 200 mg - 50 mg QD + nbUVB0/43 (0%)0/43 (0%)14/43 (32.6%)
EX PF-06651600 200mg-50mg QD0/187 (0%)1/187 (0.5%)46/187 (24.6%)
EX PF-06651600 50mg QD0/6 (0%)0/6 (0%)3/6 (50%)
EXT PF-06651600 30 mg QD0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventPF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlaceboExtension (EXT) PF-06700841 60 mg - 30 mg QDEX PF-06651600 200 mg - 50 mg QD + nbUVBEX PF-06651600 200mg-50mg QDEX PF-06651600 50mg QDEXT PF-06651600 30 mg QD
MigraineNervous system disorders0/650/671/670/501/490/660/550/430/1870/60/2
Oesophageal spasmGastrointestinal disorders0/650/670/671/500/490/660/550/430/1870/60/2
Disseminated varicella zoster virus infectionInfections and infestations0/650/670/670/500/490/661/550/430/1870/60/2
Neurogenic bladderRenal and urinary disorders0/650/670/670/500/491/660/550/430/1870/60/2
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/650/670/670/500/490/660/550/431/1870/60/2
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlaceboExtension (EXT) PF-06700841 60 mg - 30 mg QDEX PF-06651600 200 mg - 50 mg QD + nbUVBEX PF-06651600 200mg-50mg QDEX PF-06651600 50mg QDEXT PF-06651600 30 mg QD
BronchitisInfections and infestations0/651/671/673/500/490/661/550/430/1870/61/2
Urinary tract infectionInfections and infestations4/654/672/672/503/493/661/553/4312/1871/61/2
COVID-19Infections and infestations0/650/670/670/500/490/660/550/432/1870/61/2
OnychomycosisInfections and infestations0/650/670/670/500/490/660/550/430/1870/61/2
RashSkin and subcutaneous tissue disorders0/650/670/670/500/490/660/551/431/1870/61/2
NasopharyngitisInfections and infestations8/6510/6716/675/505/4914/663/550/438/1870/60/2
AnaemiaBlood and lymphatic system disorders0/650/670/670/500/490/660/550/430/1871/60/2
Ear painEar and labyrinth disorders0/650/670/670/500/490/660/550/430/1871/60/2
Influenza like illnessGeneral disorders0/650/670/670/500/490/660/550/430/1871/60/2
HypercholesterolaemiaMetabolism and nutrition disorders0/650/670/670/500/490/660/550/430/1871/60/2

Baseline characteristics

Baseline analysis population included all participants who received at least 1 dose of randomized study medication and had a baseline and at least 1 post-baseline measurement (after taking randomization study medication).

Age, Customized
Age, Customized(Participants)PF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlaceboTotal
<18 Years0000000
18 - 44 Years332933201630161
45 - 64 Years303734303132194
≥65 Years2100249
Sex: Female, Male
Sex: Female, Male(Participants)PF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlaceboTotal
Female303139282540193
Male353628222426171
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlaceboTotal
Hispanic or Latino11911127757
Not Hispanic or Latino545854384158303
Unknown or Not Reported0020114
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06651600 200 mg - 50 mg QDPF-06651600 100 mg - 50 mg QDPF-06651600 50 mg QDPF-06651600 30 mg QDPF-06651600 10 mg QDPlaceboTotal
American Indian or Alaska Native0001001
Asian1517175112186
Native Hawaiian or Other Pacific Islander0000000
Black or African American30041210
White444745393338246
More than one race0110215
Unknown or Not Reported32412416
08

Study locations

92 sites
  • Marvel Research, LLC
    Huntington Beach, California 92647, United States
  • University of California, Irvine, Dermatology Clinical Research Center
    Irvine, California 92697, United States
  • Vitiligo and Pigmentation Institute Of Southern California
    Los Angeles, California 90036, United States
  • Dermatology Specialist, Inc.
    Murrieta, California 92562, United States
  • Dermatology Specialists, Inc.
    Oceanside, California 92056, United States
  • UC Davis Health
    Sacramento, California 95816, United States
  • Brookside Dermatology Associates
    Bridgeport, Connecticut 06606, United States
  • New England Research Associates, LLC
    Bridgeport, Connecticut 06606, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Advanced Skin and MOHS Surgery Center, c/o TrialSpark, Inc.
    Chicago, Illinois 60657, United States
  • Chevy Chase Dermatology Center (TrialSpark, Inc.)
    Chevy Chase, Maryland 20815, United States
  • TrialSpark - Samantha Toerge, MD
    Chevy Chase, Maryland 20815, United States
  • TrialSpark - Ronald Shore, MD
    Rockville, Maryland 20852, United States
  • Tobias & Battite, Inc.
    Boston, Massachusetts 02111, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • UMass Memorial Medical Center, Hahnemann Campus
    Worcester, Massachusetts 01605, United States
  • Investigational Drug Service Pharmacy
    Worcester, Massachusetts 01655, United States
  • UMass Memorial Medical Center Ear Nose and Throat
    Worcester, Massachusetts 01655, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • Henry Ford Hospital Department of Dermatology
    Detroit, Michigan 48202, United States
  • University of Minnesota Department of Dermatology
    Minneapolis, Minnesota 55455, United States
  • The Dermatology Group, P.C.
    Verona, New Jersey 07044, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10003, United States
  • Upper West Side Dermatology c/o TrialSpark, Inc
    New York, New York 10023, United States
  • MDCS: Medical Dermatology & Cosmetic Surgery (TrialSpark, Inc.)
    New York, New York 10065, United States
  • South Nassau Dermatology
    Oceanside, New York 11572, United States
  • TrialSpark, Inc. - Russell W. Cohen, MD
    Oceanside, New York 11572, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28411, United States
  • Remington-Davis, Inc. Clinical Research
    Columbus, Ohio 43215, United States
  • ForeFront Dermatology
    Columbus, Ohio 43220, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 74136, United States
  • University Physicians Group
    Austin, Texas 78701, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9191, United States
  • Pickens Academic Tower
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Clinical Research, Inc
    Norfolk, Virginia 23502, United States
  • Tamjidi Skin Institute (TrialSpark, Inc.)
    Vienna, Virginia 22182, United States
  • The Skin Hospital
    Darlinghurst, New South Wales 2010, Australia
  • Premier Specialists Pty Ltd
    Kogarah, New South Wales 2217, Australia
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3052, Australia
  • Hôpital Erasme Dermatology
    Brussels, 1070, Belgium
  • UZ Brussel - Dermatology
    Brussel, 1090, Belgium
  • UZ Gent - Dermatology
    Gent, 9000, Belgium
  • Dr. Chih-ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
  • University of British Columbia
    Vancouver, British Columbia V5Z 4E8, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • CCA Medical Research
    Ajax, Ontario L1S 7K8, Canada
  • Guenther Research Inc.
    London, Ontario N6A 3H7, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X3, Canada
  • DermEdge Research
    Mississauga, Ontario L5H 1G9, Canada
  • North York Research Inc.
    North York, Ontario M2M 4J5, Canada
  • The Centre for Clinical Trials
    Oakville, Ontario L6J 7W5, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • K.Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2X 2V1, Canada
  • Diex Research Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
    Quebec, G1V 4X7, Canada
  • Centre de Recherche Saint-Louis
    Quebec, G1W 4R4, Canada
  • Centre de Recherche Saint-Louis
    Quebec, G1W1S2, Canada
  • Fachklinik Bad Bentheim, Fachbereich Dermatologie und Allergologie, Dermatologische Ambulanz
    Bad Bentheim, 48455, Germany
  • Universitaetsklinikum Erlangen Hautklinik Studienambulanz
    Erlangen, 91054, Germany
  • Universitätsklinikum Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie
    Frankfurt am Main, 60590, Germany
  • Universitaetsklinikum Schleswig-Holstein, Campus Luebeck CCIM
    Luebeck, 23538, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, 55131, Germany
  • Universitaetsklinikum Muenster
    Muenster, 48149, Germany
  • Istituti Fisioterapici Ospitalieri, Istituto di Ricovero e Cura a Carattere Scientifico,
    Roma, RM 00144, Italy
  • Nagoya City University Hospital - Dermatology
    Nagoya, Aichi 467-8602, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Nippon Medical School Hospital
    Bunkyo-ku, Tokyo 113-8603, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Yamanashi Prefectural Central Hospital
    Kofu, Yamanashi 400-8506, Japan
  • Dongguk University Ilsan Hospital
    Goyang-si, Gyeonggi-do 10326, Korea, Republic of
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon-si, Gyeonggi-do 16247, Korea, Republic of
  • Ajou University Hospital
    Suwon, Gyeonggi-do 16499, Korea, Republic of
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, 14004, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, 83301, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
09

References and documents

Publications

  • Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaci D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. Erratum In: J Am Acad Dermatol. 2023 Sep;89(3):639. doi: 10.1016/j.jaad.2023.04.001. PubMed 36370907 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Feb 2021, 26 months.

Results were first posted in Mar 2022, 1 year 1 month after primary completion.

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2018
First posted
Oct 23, 2018
StartActual
Nov 26, 2018
Primary completionActual
Feb 5, 2021
CompletionActual
Feb 5, 2021
Results first posted
Mar 25, 2022
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03715829
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 23, 2018
Start date
Nov 26, 2018
Primary completion
Feb 5, 2021
Completion
Feb 5, 2021
Results posted
Mar 25, 2022
Last update
Mar 25, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-06651600 · PF-06700841

Start the discussion